Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

9.710 +0.090 (+0.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Details for Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
Xeris Announces Changes to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Expects to Exceed Full-Year 2024 Financial Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference
From Xeris Biopharma
Via Business Wire
Xeris Biopharma Reports Third Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in Upcoming Investor Conferences
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Reports Second Quarter 2024 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces CEO Succession Plan
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
Xeris to Participate in the Jefferies Global Healthcare Conference
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.